Profile data is unavailable for this security.
About the company
Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.
- Revenue in SEK (TTM)186.00k
- Net income in SEK-139.62m
- Incorporated1984
- Employees25.00
- LocationDiamyd Medical ABKungsgatan 29STOCKHOLM 111 56SwedenSWE
- Phone+46 86610026
- Fax+46 86616368
- Websitehttps://www.diamyd.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alligator Bioscience AB | 45.71m | -234.30m | 1.10bn | 51.00 | -- | -- | -- | 24.15 | -0.362 | -0.362 | 0.0696 | -0.0125 | 0.2653 | -- | 9.47 | 788,034.50 | -136.02 | -73.26 | -367.94 | -91.33 | -- | -- | -512.61 | -811.68 | -- | -35.61 | 5.17 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Arcticzymes Technologies ASA | 115.86m | 17.27m | 1.24bn | 68.00 | 71.88 | 4.01 | 53.02 | 10.74 | 0.3443 | 0.3443 | 2.30 | 6.17 | 0.3562 | 0.4228 | 6.29 | 1,731,471.00 | 5.31 | 15.58 | 5.66 | 17.22 | 95.50 | 96.69 | 14.91 | 33.23 | 12.14 | -- | 0.0327 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
| XSpray Pharma AB (publ) | 0.00 | -212.58m | 1.59bn | 26.00 | -- | 2.90 | -- | -- | -7.66 | -7.66 | 0.00 | 20.00 | 0.00 | -- | -- | 0.00 | -33.92 | -18.38 | -36.11 | -19.26 | -- | -- | -- | -- | 2.24 | -- | 0.0536 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Diamyd Medical AB | 186.00k | -139.62m | 1.66bn | 25.00 | -- | 8.76 | -- | 8,933.09 | -1.55 | -1.55 | 0.0021 | 1.96 | 0.0009 | -- | 3.35 | 7,440.00 | -68.99 | -25.46 | -76.65 | -28.37 | -7,386.02 | -1,419.23 | -75,065.59 | -5,896.43 | -- | -90.74 | 0.1391 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| Cereno Scientific AB | 0.00 | -59.13m | 1.69bn | 5.00 | -- | 7.00 | -- | -- | -0.281 | -0.281 | 0.00 | 0.8598 | 0.00 | -- | -- | 0.00 | -24.71 | -16.81 | -26.65 | -18.26 | -- | -- | -- | -- | -- | -10.70 | 0.1843 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Nanoform Finland Oyj | 28.40m | -272.23m | 1.77bn | 166.00 | -- | 2.28 | -- | 62.26 | -0.2974 | -0.2974 | 0.031 | 0.774 | 0.0287 | 100.58 | 4.29 | 14,687.82 | -27.47 | -27.13 | -30.12 | -29.48 | -576.50 | -604.26 | -958.65 | -1,023.70 | 6.60 | -- | 0.091 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Egetis Therapeutics AB (publ) | 62.80m | -326.90m | 1.79bn | 30.00 | -- | 3.79 | -- | 28.51 | -1.22 | -1.22 | 0.2326 | 1.62 | 0.0913 | 28.00 | 4.33 | 2,325,926.00 | -47.48 | -33.02 | -53.33 | -36.46 | 82.17 | -- | -520.22 | -357.72 | 2.53 | -144.77 | 0.2014 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Devyser Diagnostics AB | 196.00m | -54.20m | 1.81bn | 127.00 | -- | 4.92 | -- | 9.25 | -3.33 | -3.33 | 12.05 | 22.35 | 0.3855 | 1.61 | 5.42 | 1,661,017.00 | -10.68 | -8.97 | -12.15 | -10.15 | 83.11 | 80.14 | -27.70 | -23.91 | 4.01 | -- | 0.1498 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
| Vicore Pharma Holding AB | 104.24m | -212.94m | 2.07bn | 26.00 | -- | 4.23 | -- | 19.85 | -2.15 | -2.15 | 1.01 | 4.38 | 0.2589 | -- | 14.41 | 4,343,459.00 | -52.89 | -58.65 | -59.34 | -65.58 | -- | -- | -204.27 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
Data as of Jul 30 2024. Currency figures normalised to Diamyd Medical AB's reporting currency: Swedish Krona SEK
0.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Evli Fund Management Co. Ltd.as of 28 Jun 2024 | 33.00k | 0.03% |
Data from 28 Jun 2024 - 28 Jun 2024Source: FactSet Research Systems Inc.
